Danish pharmaceutical company Novo Nordisk A/S (CPH:NOVO-B) (NYSE:NVO) on Tuesday reported positive phase 2 results for amycretin in people with type 2 diabetes, showing statistically significant weight loss of up to 14.5% and HbA1c reductions with up to 89.1% of participants reaching levels below 7%.

The unimolecular GLP-1 and amylin agonist was evaluated as a once-weekly subcutaneous treatment and a once-daily oral option in 448 adults with type 2 diabetes inadequately controlled on metformin with or without an SGLT2 inhibitor.

The study tested six subcutaneous doses and three oral doses over 36 weeks, delivering dose-dependent HbA1c reductions of up to -1.8% and -1.5%, respectively, compared with placebo outcomes of -0.2% and -0.4%.

Participants receiving amycretin achieved statistically significant weight loss of up to 14.5% with subcutaneous dosing and 10.1% with oral dosing, while no weight-loss plateau was observed at week 36.

Safety findings indicated a profile consistent with incretin and amylin-based therapies, with gastrointestinal events largely mild to moderate.

Novo Nordisk plans to advance amycretin into phase 3 development for adults with type 2 diabetes in 2026.